AU2005336881A1 - Histone deacetylase whole cell enzyme assay - Google Patents
Histone deacetylase whole cell enzyme assay Download PDFInfo
- Publication number
- AU2005336881A1 AU2005336881A1 AU2005336881A AU2005336881A AU2005336881A1 AU 2005336881 A1 AU2005336881 A1 AU 2005336881A1 AU 2005336881 A AU2005336881 A AU 2005336881A AU 2005336881 A AU2005336881 A AU 2005336881A AU 2005336881 A1 AU2005336881 A1 AU 2005336881A1
- Authority
- AU
- Australia
- Prior art keywords
- family
- protein deacetylase
- reporter molecule
- isotype
- substrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000003964 Histone deacetylase Human genes 0.000 title claims description 499
- 108090000353 Histone deacetylase Proteins 0.000 title claims description 499
- 238000001952 enzyme assay Methods 0.000 title description 6
- 239000000758 substrate Substances 0.000 claims description 227
- 230000000694 effects Effects 0.000 claims description 164
- 241000124008 Mammalia Species 0.000 claims description 142
- 239000003112 inhibitor Substances 0.000 claims description 114
- 238000000034 method Methods 0.000 claims description 112
- 210000001124 body fluid Anatomy 0.000 claims description 106
- 239000012190 activator Substances 0.000 claims description 71
- 230000006196 deacetylation Effects 0.000 claims description 46
- 238000003381 deacetylation reaction Methods 0.000 claims description 46
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 claims description 35
- 238000001727 in vivo Methods 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 description 236
- 102000011990 Sirtuin Human genes 0.000 description 41
- 108050002485 Sirtuin Proteins 0.000 description 41
- 210000000265 leukocyte Anatomy 0.000 description 38
- 229940125782 compound 2 Drugs 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- SUTRDULVNIPNLW-SFHVURJKSA-N tert-butyl n-[(2s)-6-acetamido-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxohexan-2-yl]carbamate Chemical compound CC1=CC(=O)OC2=CC(NC(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCNC(=O)C)=CC=C21 SUTRDULVNIPNLW-SFHVURJKSA-N 0.000 description 25
- 238000003556 assay Methods 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 231100000673 dose–response relationship Toxicity 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 108010033040 Histones Proteins 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 14
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 14
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 13
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 13
- 229960005314 suramin Drugs 0.000 description 13
- 102000006947 Histones Human genes 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 9
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 9
- 230000006195 histone acetylation Effects 0.000 description 9
- 229940016667 resveratrol Drugs 0.000 description 9
- 235000021283 resveratrol Nutrition 0.000 description 9
- 150000003384 small molecules Chemical class 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 7
- 206010036790 Productive cough Diseases 0.000 description 6
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000007914 intraventricular administration Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 5
- 102000000477 Sirtuin 2 Human genes 0.000 description 5
- 108010041216 Sirtuin 2 Proteins 0.000 description 5
- 239000012131 assay buffer Substances 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000021736 acetylation Effects 0.000 description 4
- 238000006640 acetylation reaction Methods 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000000478 Sirtuin 3 Human genes 0.000 description 3
- 108010041218 Sirtuin 3 Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108010024124 Histone Deacetylase 1 Proteins 0.000 description 2
- 102100022537 Histone deacetylase 6 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002583 anti-histone Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- -1 taxol compound Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 229940122964 Deacetylase inhibitor Drugs 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108010023925 Histone Deacetylase 6 Proteins 0.000 description 1
- 101000899330 Homo sapiens Histone deacetylase 6 Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- WWGBHDIHIVGYLZ-UHFFFAOYSA-N N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester Chemical compound C1=CC(NC(=O)OC(C)(C)C)=CC=C1C1=CC(C(=O)NCCCCCCC(=O)NO)=NO1 WWGBHDIHIVGYLZ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 229940078753 Sirtuin inhibitor Drugs 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000021738 protein deacetylation Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61196404P | 2004-09-22 | 2004-09-22 | |
| US60/611,964 | 2004-09-22 | ||
| PCT/IB2005/004207 WO2007135471A1 (en) | 2004-09-22 | 2005-09-21 | Histone deacetylase whole cell enzyme assay |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005336881A1 true AU2005336881A1 (en) | 2007-05-24 |
| AU2005336881A8 AU2005336881A8 (en) | 2008-08-07 |
Family
ID=38093181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005336881A Abandoned AU2005336881A1 (en) | 2004-09-22 | 2005-09-21 | Histone deacetylase whole cell enzyme assay |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060063210A1 (https=) |
| EP (1) | EP1922414A4 (https=) |
| JP (1) | JP2008532561A (https=) |
| AU (1) | AU2005336881A1 (https=) |
| CA (1) | CA2581356A1 (https=) |
| WO (1) | WO2007135471A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6897220B2 (en) * | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US20080199897A1 (en) * | 2007-02-05 | 2008-08-21 | Methylgene Inc. | Class ii histone deacetylase whole cell enzyme assay |
| US8030344B2 (en) * | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US9636298B2 (en) | 2014-01-17 | 2017-05-02 | Methylgene Inc. | Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2093292A2 (en) * | 2000-03-24 | 2009-08-26 | Methylgene, Inc. | Inhibition of specific histone deacetylase isoforms |
-
2005
- 2005-09-21 WO PCT/IB2005/004207 patent/WO2007135471A1/en not_active Ceased
- 2005-09-21 CA CA002581356A patent/CA2581356A1/en not_active Abandoned
- 2005-09-21 EP EP05858685A patent/EP1922414A4/en not_active Withdrawn
- 2005-09-21 AU AU2005336881A patent/AU2005336881A1/en not_active Abandoned
- 2005-09-21 JP JP2008516423A patent/JP2008532561A/ja not_active Withdrawn
- 2005-09-21 US US11/231,528 patent/US20060063210A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005336881A8 (en) | 2008-08-07 |
| EP1922414A1 (en) | 2008-05-21 |
| EP1922414A4 (en) | 2008-11-05 |
| US20060063210A1 (en) | 2006-03-23 |
| WO2007135471A1 (en) | 2007-11-29 |
| JP2008532561A (ja) | 2008-08-21 |
| CA2581356A1 (en) | 2006-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | METTL3 acetylation impedes cancer metastasis via fine-tuning its nuclear and cytosolic functions | |
| Gunaratne et al. | NAADP-dependent Ca2+ signaling regulates Middle East respiratory syndrome-coronavirus pseudovirus translocation through the endolysosomal system | |
| Fitzgerald et al. | Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease | |
| Gertz et al. | Using mitochondrial sirtuins as drug targets: disease implications and available compounds | |
| Vempati et al. | p300-mediated acetylation of histone H3 lysine 56 functions in DNA damage response in mammals | |
| Bonfils et al. | Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay | |
| Sengupta et al. | Human sirtuin 3 (SIRT3) deacetylates histone H3 lysine 56 to promote nonhomologous end joining repair | |
| Cenni et al. | Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria | |
| Li et al. | The interaction between acetylation and serine-574 phosphorylation regulates the apoptotic function of FOXO3 | |
| Kiprowska et al. | Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease | |
| Cen et al. | Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications | |
| Kang et al. | Acetylated 8-oxoguanine DNA glycosylase 1 and its relationship with p300 and SIRT1 in lens epithelium cells from age-related cataract | |
| Mattioli et al. | Statins and histone deacetylase inhibitors affect lamin A/C–histone deacetylase 2 interaction in human cells | |
| US20110287026A1 (en) | Sirt4 and uses thereof | |
| Chi et al. | Honokiol ameliorates angiotensin II‐induced hypertension and endothelial dysfunction by inhibiting HDAC6‐mediated cystathionine γ‐lyase degradation | |
| US11708609B2 (en) | Methods of diagnosing alzheimer's disease and risk of progression to alzheimer's disease | |
| Cushman et al. | Role of isoprenylcysteine carboxylmethyltransferase-catalyzed methylation in Rho function and migration | |
| Lund et al. | Adenosine 3′, 5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors | |
| Wang et al. | Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells | |
| Shokeen et al. | Newcastle disease virus regulates its replication by instigating oxidative stress-driven Sirtuin 7 production | |
| US20060063210A1 (en) | Histone deacetylase whole cell enzyme assay | |
| US20100310574A1 (en) | Methods and compositions for the treatment and diagnosis of statin-induced myopathy | |
| Capanni et al. | Emerin—prelamin A interplay in human fibroblasts | |
| Kim et al. | G9a/GLP methyltransferases inhibit autophagy by methylation-mediated ATG12 protein degradation | |
| US20110184052A1 (en) | Arginase ii: a target for the prevention and treatment of atherosclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TC | Change of applicant's name (sec. 104) |
Owner name: METHLGENE INC. Free format text: FORMER NAME: METHLGENE, INC. |
|
| TH | Corrigenda |
Free format text: IN VOL 21, NO 20, PAGE(S) 2325 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME METHYLGENE INC., APPLICATION NO. 2005336881, UNDER INID(43), CORRECT THE DATE TO READ 29.11.07 Free format text: IN VOL 21, NO 20, PAGE(S) 2363 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME METHYLGENE INC., APPLICATION NO. 2005336881, UNDER INID(43), CORRECT THE DATE TO READ 29.11.07 |
|
| TH | Corrigenda |
Free format text: IN VOL 21, NO 20, PAGE(S) 2363 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME METHYLGENE INC., APPLICATION NO. 2005336881, UNDER INID(43), CORRECT THE DATE TO READ 29.11.07 Free format text: IN VOL 21, NO 20, PAGE(S) 2325 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME METHYLGENE INC., APPLICATION NO. 2005336881, UNDER INID(43), CORRECT THE DATE TO READ 29.11.07 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |